A comparison of the blood pressure changes of lumiracoxib with those of ibuprofen and naproxen.

Author(s): Farkouh ME, Verheugt FW, Ruland S, Kirshner H, Jeger R, Gitton X, Krammer G, Stricker K, Sallstig P, Mellein B, Matchaba P, Chesebro JH

Affiliation(s): Clinical Trials Unit, Mount Sinai Cardiovascular Institute, New York, NY 10029, USA. michael.farkouh@mssm.edu

Publication date & source: 2008-08, J Clin Hypertens (Greenwich)., 10(8):592-602.

Publication type: Comparative Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

The 52-week Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET) investigated the gastrointestinal and cardiovascular safety profile of lumiracoxib 400 mg once daily compared with 2 traditional nonsteroidal anti-inflammatory drugs (NSAIDs): ibuprofen 800 mg 3 times daily and naproxen 500 mg twice daily. Data from TARGET were analyzed to examine the effect of lumiracoxib compared with ibuprofen and naproxen on blood pressure (BP), incidence of de novo and aggravated hypertension, prespecified edema events, and congestive heart failure. Lumiracoxib resulted in smaller changes in BP as early as week 4. Least-squares mean change from baseline at week 4 for systolic BP was +0.57 mm Hg with lumiracoxib compared with +3.14 mm Hg with ibuprofen (P<.0001) and +0.43 with lumiracoxib compared with +1.80 mm Hg with naproxen (P<.0001). In conclusion, the use of lumiracoxib and traditional NSAIDs results in differing BP changes; these might be of clinical relevance.